Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 937-221-5 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Study period:
- 16-JUL-2007 to 31-OCT-2008
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: The study was performed according to OECD guideline 422 and in compliance with GLP. However, as the data are used in a read-across approach, the maximal reliability score was decreased from 1 to 2, according to Practical Guide n°6.
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 008
- Report date:
- 2008
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- Dicerium tricarbonate
- EC Number:
- 208-655-6
- EC Name:
- Dicerium tricarbonate
- Cas Number:
- 537-01-9
- IUPAC Name:
- dicerium tricarbonate
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Janvier, Le Genest-Saint-Isle, France
- Age at study initiation: Approximately 10 weeks old at the beginning of the treatment period
- Weight at study initiation: At the beginning of the treatment period, the animals had a mean body weight of 419 g (range: 392 g to 442 g) for the males and 263 g (range: 239 g to 283 g) for the females
- Fasting period before study: No
- Housing: The males were individually housed, except during pairing, in wire-mesh cages (43.0 x 21.5 x 18.0 cm). The females were individually housed, except during pairing, until late gestation in wire-mesh cages (43.0 x 21.5 x 18.0 cm). The females were individually housed from late gestation, and with their litter during lactation, in polycarbonate cages (43.0 x 21.5 x 20.0 cm).
- Diet: Free access to SSNIFF R/M-H pelleted maintenance diet
- Water: Free access to bottles containing tap water (filtered with a 0.22 µm filter)
- Acclimation period: The animals were acclimated to the study conditions for a period of 7 days before the beginning of the treatment period.
ENVIRONMENTAL CONDITIONS
- Temperature: 22 ± 2°C
- Humidity: 50 ± 20%
- Air changes: About 12 cycles/hour of filtered, non-recycled air
- Photoperiod: 12 hrs dark / 12 hrs light
IN-LIFE DATES: From 14-AUG-2007 to 10-OCT-2007
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 0.5% aqueous methylcellulose solution
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test item was administered as a suspension in the vehicle. The test item was ground to fine powder using a mortar and pestle, suspended in the vehicle in order to achieve the concentrations of 30, 90 and 200 mg/mL and then homogenized using a magnetic stirrer. The test item dosage forms were prepared at a frequency based on stability data (up to 9 days) and were stored at +4°C, protected from light, prior to use.
VEHICLE
- Justification for use and choice of vehicle (if other than water): Aqueous suspension for a poorly hydrosoluble test substance, as recommended in the guideline
- Concentration in vehicle: 30, 90 and 200 mg/mL
- Amount of vehicle (if gavage): A constant volume of 5 mL/kg/day was used
- Lot/batch no. (if required): Methylcellulose batch No. 017K0052, supplied by Sigma
- Purity: No data available - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- During a pre-study period, the homogeneity, stability and concentration of two dosage forms prepared at the lowest and highest concentrations of the present study (30 and 200 mg/mL) were checked using ICP-OES (Inductively Coupled Plasma/Optical Emission Spectrometry) after validation of the analytical method. The results showed acceptable homogeneity and stability of both concentrations over 9 days at +4°C.
During the study, the concentration of the test item and homogeneity of the dosage forms was determined in samples of each control and test item dosage form prepared for use in weeks 1, 3 and 6. The results showed acceptable homogeneity and concentration of all dosage forms analyzed. Precision (RSD ≤ 10%) and accuracy (100 ± 10%) of the method were found to be satisfactory. - Details on mating procedure:
- - M/F ratio per cage: One female was placed with one male
- Length of cohabitation: Each female was placed with the same male until mating occurs or 14 days had elapsed. Any pairs with no evidence of mating after 14 days were separated and the female was placed for 7 days with a different male from the same dose level group who had already mated.
- Proof of pregnancy: Confirmation of mating was made in the morning, every day up to proof of mating, by checking for the presence of a vaginal plug or of sperm in a vaginal lavage.
- Further matings after two unsuccessful attempts: No
- After successful mating each pregnant female was caged (how): Individually
- Any other deviations from standard protocol: No - Duration of treatment / exposure:
- - In parent males: 15 days before mating, during the mating period (up to 3 weeks), until sacrifice (i.e. at least 4 weeks in total)
- In parent females: 15 days before mating, during the mating period (up to 3 weeks), during pregnancy, during lactation until day 5 post-partum inclusive - Frequency of treatment:
- Each animal was given the appropriate dosage form once a day, at approximately the same time each day, 7 days a week.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 150, 450, and 1000 mg/kg bw/day
Basis:
other: nominal conc. corrected from the water content
- No. of animals per sex per dose:
- 10 males and 10 females per group
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: On the basis of a previous 14-day toxicity study in the rat in which the dose-levels of 150, 450 and 1000 mg/kg/day elicited no significant treatment-related effects.
- Rationale for animal assignment: During the pre-treatment period, the required number of animals (40 males and 40 females) was selected according to body weight and clinical condition and allocated to the groups (by sex), according to a computerized stratification procedure, so that the average body weight of each group was similar.
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: From arrival, the animals were observed once a day as part of routine examinations. From the start of treatment period, each animal was observed once a day, at approximately the same time for the recording of clinical signs.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: On all animals outside the home cage, in a standard arena, once before the beginning of the treatment period and then once a week until the end of the study.
Observations included (but were not limited to) changes in the skin, fur, eyes, mucous membranes, occurrence of secretions and excretions and autonomic activity (e.g. lachrymation, piloerection, pupil size, unusual respiratory pattern). Changes in gait, posture and response to handling as well as the presence of clonic or tonic movements, stereotypes (e.g. excessive grooming, repetitive circling) or bizarre behavior (e.g. self-mutilation, walking backwards) were also recorded.
BODY WEIGHT: Yes
- Time schedule for examinations: The body weight of each female was recorded on the first day of treatment (day 1), then once a week until mated (or until sacrifice) and on days 0, 7, 14 and 20 post-coitum and days 1 and 5 post-partum.
FOOD CONSUMPTION: Yes
The quantity of food consumed by each female was recorded once a week, over a 7 day period, from the first day of treatment through gestation (days 0-7, 7-14 and 14-20 post-coitum intervals) and lactation (days 1-5 post-partum intervals) until sacrifice. During the pairing period, food consumption was not recorded.
WATER CONSUMPTION: No
POST-MORTEM EXAMINATIONS: Yes
On day 6 post-partum, after overnight fasting, at least 14 hours, all surviving parental females were deeply anesthetized by an intraperitoneal injection of sodium pentobarbital and sacrificed by exsanguination:
- A complete macroscopic post-mortem examination was performed on all animals. This included examination of the external surfaces, all orifices, the cranial cavity, the external surfaces of the brain, the thoracic, abdominal and pelvic cavities with their associated organs and tissues and the neck with its associated organs and tissues. Special attention was paid to the reproductive organs. The numbers of corpora lutea and implantation sites were also recorded.
A microscopic examination was performed on:
- All the tissues listed in the Table 1 for the first five females of the control and high-dose groups (groups 1 and 4) sacrificed as scheduled
- All macroscopic lesions
OTHER:
MORTALITY AND MORBIDITY: Each animal was checked for mortality or signs of morbidity at least twice a day during the treatment period.
Functional Observation Battery (FOB): on the first five females, once at the end of the treatment period. This included a detailed clinical examination, measurement of reactivity to manipulation or to different stimuli and motor activity.
HEMATOLOGY: Peripheral blood
The following parameters were determined for the last five females of each group on the day of sacrifice: Erythrocytes, Hemoglobin, Mean cell volume, Packed cell volum, Mean cell hemoglobin concentration, Mean cell hemoglobin, Thrombocytes, Leucocytes, Differential white cell count with cell morphology (neutrophils, eosinophils, basophils, lymphocytes and Large Unstained Cells), Monocytes, Reticulocytes, Prothrombin time, Activated partial thromboplastin time, Fibrinogen.
BLOOD BIOCHEMISTRY:
The following parameters were determined for the last five females of each group on the day of sacrifice: Sodium, Potassium, Chloride, Calcium, Inorganic phosphorus, Glucose, Urea, Creatinine, Total bilirubin, Total proteins, Albumin, Albumin/globulin ratio, Total cholesterol, Triglycerides, Alkaline phosphatase, Aspartate aminotransferase, Alanine aminotransferase, Lactate dehydrogenase, Bile acids - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: No
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: Mating index, fertility index, gestation index, number of pups delivered - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: No
- Skeletal examinations: No
- Head examinations: No
- Other: Live birth index, viability index on day 4 post-partum, mean litter size, and pup sex ratios - Statistics:
- Mean values were compared by one-way variance analysis and Dunnett test, (mean values being considered as normally distributed, variances being considered as homogeneous). Percentage values were compared by Fisher exact probability test.
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:yes
Details on maternal toxic effects:
CLINICAL SIGNS AND MORTALITY: There were no treatment-related mortalities or clinical signs.
BODY WEIGHT AND FOOD CONSUMPTION: Females had lower mean body weight gains during pregnancy and lactation and lower food consumption during lactation but this may be related to the higher number of fetuses/pups in the control group. There were no effects during the pre-mating period and no effects on mean male body weight or food consumption.
REPRODUCTIVE FUNCTION: Mating performance, fertility indices, corpora lutea and implantation counts, duration of gestation, and the mean number of live pups born per litter, were similar between control females and females receiving the test material. The data are summarised in Tables 2, 3 and 4.
HAEMATOLOGY: Females treated at 1000 mg/kg bw/day had a decrease in white blood cell count (approximately 12%) when compared with control.
CLINICAL CHEMISTRY: Females treated at 1000 mg/kg bw/day had a decrease in chloride concentration and an increase in glucose, potassium, inorganic phosphorus and urea concentrations.
NEUROBEHAVIOUR: A majority of animals treated at 1000 mg/kg bw/day had an increased number of horizontal movements during the 1-hour motor activity test but there were no other effects of treatment observed during the tests performed in the functional observation battery.
HISTOPATHOLOGY: NON-NEOPLASTIC: There was microscopic treatment related in the stomach that consisted of increased incidence and/or severity of submucosal eosinophil infiltration and pyloric gland hyperplasia in rats from both sexes treated at 1000 mg/kg bw/day and 450 mg/kg bw/day. No microscopic treatment related changes were observed in the testes and ovaries.
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 450 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- NOEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
Mating performance, fertility indices, corpora lutea and implantation counts, duration of gestation, and the mean number of live pups born per litter, were similar between control females and females receiving the test material. The data are summarised in Tables 2, 3 and 4.
There were no effects on pup survival after birth or on pup sex. Mean pup body weight was higher at all dose-levels but the mean body weight gain was comparable to the controls. There were no relevant macroscopic findings at pup necropsy.
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Any other information on results incl. tables
Table 2: Summary of reproductive data
Dose level (mg/kg bw/d) |
0 |
150 |
450 |
1000 |
|
Paired males + females |
n |
10 + 10 |
10 + 10 |
10 + 10 |
10 + 10 |
Pairs mated |
n |
10 |
10 |
9 (10) |
10 |
Mating index |
% |
100.0 |
100.0 |
90.0 (100.0) |
100.0 |
Mean number of days of pairing before mating |
n |
3.4 |
2.4 |
4.3 |
2.3 |
Pregnant female partners |
n |
10 |
8 |
10 |
10 |
Fertility index |
% |
100.0 |
80.0 |
100.0 |
100.0 |
Females with live concepti |
n |
10 |
8 |
10 |
10 |
Gestation index |
% |
100.0 |
100.0 |
100.0 |
100.0 |
( ): female with no evidence of mating
Table 3: Summary of delivery data
Dose level (mg/kg bw/day) |
0 |
150 |
450 |
1000 |
Number of pregnant females Mean duration of gestation (days) Mean number of corpora lutea Mean number of implantations Mean pre-implantation loss (%) Mean number of pups delivered Mean post-implantation loss (%) |
10 21.8 18.6 16.5 11.3 15.6 5.7 |
8 21.9 17.6 16.5 5.6 14.6 11.6 |
10 22.1 18.5 15.1 17.0 12.0 22.2 |
10 22.0 18.0 14.7 17.4 12.9 12.3 |
Table 4: Reproductive and litter data
Doses (mg/kg bw/day) |
0 |
150 |
450 |
1000 |
|
Females on study |
N |
10 |
10 |
10 |
10 |
Females mated |
N |
10 |
10 |
10 |
10 |
Mating index |
% |
100.0 |
100.0 |
100.0 |
100.0 |
Females pregnant |
N |
10 |
8 |
10 |
10 |
Females fertility index |
% |
100.0 |
80.0 |
100.0 |
100.0 |
Females with liveborn |
N |
10 |
8 |
10 |
10 |
Gestation index |
% |
100.0 |
100.0 |
100.0 |
100.0 |
Females surviving delivery |
N |
10 |
8 |
10 |
10 |
Duration of gestation |
Mean S.D. |
21.8 days 0.4 |
21.9 0.4 |
22.1 0.6 |
22.0 0.0 |
With stillborn pups |
N % |
0 0.0 |
0 0.0 |
0 0.0 |
0 0.0 |
With all stillborn |
N % |
0 0.0 |
0 0.0 |
0 0.0 |
0 0.0 |
With entire liveborn litter dying and/or missing, cannibalized, culled |
|||||
Days 0-4 |
N % |
0 0.0 |
0 0.0 |
1 10.0 |
0 0.0 |
Days 0-5 |
N % |
0 0.0 |
0 0.0 |
1 10.0 |
0 0.0 |
Litters with liveborn pups |
N |
10 |
8 |
10 |
10 |
Pups delivered (total) |
N |
156 |
117 |
120 |
129 |
Liveborn |
Mean S.D. |
15.6 2.7 |
14.6 2.3 |
12.0 5.2 |
12.9 4.4 |
Live birth index |
N % |
156 100.0 |
117 100.0 |
120 100.0 |
129 100.0 |
Stillborn |
N % |
0 0.0 |
0 0.0 |
0 0.0 |
0 0.0 |
Culled (total) |
N |
0 |
0 |
0 |
0 |
Cannibalized |
N |
2 |
4 |
2 |
0 |
Missing |
N |
0 |
0 |
0 |
0 |
Died |
N |
4 |
1 |
1 |
1 |
Liveborn, not culled prior to day 5 |
N |
156 |
117 |
120 |
129 |
Pups dying, missing and/or cannibalized |
|||||
Day 0 |
N % |
0 0.0 |
0 0.0 |
0 0.0 |
0 0.0 |
Days 1-4 |
N % |
6 3.8 |
5 4.3 |
3 2.5 |
1 0.8 |
Days 5-7 |
N % |
0 0.0 |
0 0.0 |
0 0.0 |
0 0.0 |
Pups surviving 4 days |
N |
150 |
112 |
117 |
128 |
Viability index |
% |
96.2 |
95.7 |
97.5 |
99.2 |
d = ANOVA + Dunnett-test
f = Fishers exact Test
N = number of animals
Applicant's summary and conclusion
- Conclusions:
- Under the conditions of this study in Sprague-Dawley strain rats the No Observed Adverse Effect Level (NOAEL) of dicerium tricarbonate for maternal toxicity was considered to be 450 mg/kg bw/day (based on systemic effects) and the No Observed Effect Level (NOEL) for developmental effects was considered to be 1000 mg/kg bw/day.
- Executive summary:
A combined repeated dose toxicity study with reproduction/developmental toxicity screening test was carried out in order to assess the test material, dicerium tricarbonate, in accordance with the standardised guideline OECD 422.
Three groups of 10 male and 10 female Sprague-Dawley rats were dosed once daily, by oral gavage, with the test material at dose levels of 150, 450, or 1000 mg/kg bw/day. Another group of 10 male and 10 female rats were dosed with the vehicle (0.5 % w/v methylcellulose) following the same dosing regimen as the treated animals and were used as controls.
The males were treated for 2 weeks prior to mating, then through mating, until the day prior to necropsy (ca. 4 weeks of treatment). Females were treated for 2 weeks prior to mating, then through mating, gestation and until at least Day 4 of lactation (ca. 8 weeks of treatment).
The following parameters and end points were evaluated: clinical signs, bodyweights, bodyweight changes, food consumption, ophthalmology, detailed functional tests and observations, clinical pathology parameters (haematology, coagulation and clinical chemistry), gross necropsy findings, organ weights, and histopathological examinations, mating and pregnancy performance, fertility, maternal care and pup performance (litter survival and pup weights).
There were no adverse effects of treatment at any dose-level on mortality, clinical signs, body weight or food consumption. There were no treatment-related organ weights and macroscopic changes in female rats treated at 1000 mg/kg/day. No microscopic treatment related changes were observed in ovaries. However, females treated at 1000 mg/kg/day had lower white blood cell counts, lower chloride concentration and higher glucose, potassium, inorganic phosphorus and urea levels. Moreover, there were microscopic treatment related findings in the stomach that consisted of increased incidence and/or severity of submucosal eosinophil infiltration and pyloric gland hyperplasia in rats from both sexes treated at 1000 mg/kg/day and males at 450 mg/kg/kg. However, the microscopic findings in the stomach were likely to be related to portal-of-entry irritating effects, due to the high concentrations of the substance given as a bolus by gavage.
Mating performance, fertility indices, corpora lutea and implantation counts, duration of gestation, and the mean number of live pups born per litter were similar between control and treated females. Litter survival, litter weights and mean pup weights were similar between litters derived from control and treated females.
In conclusion, under the conditions of this study the No Observed Adverse Effect Level (NOAEL) for maternal toxicity was considered to be 450 mg/kg bw/day (based on systemic effects) and No Observed Effect Level (NOEL) for developmental effects was considered to be 1000 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.